Premium Partner

TBPP_Economics and Trends in the Plasma Industry

TBPP_Economics and Trends in the Plasma Industry

TBPP_Economics and Trends in the Plasma Industry


Kartei Details

Karten 12
Sprache English
Kategorie Chemie
Stufe Universität
Erstellt / Aktualisiert 01.01.2017 / 01.01.2017
Lizenzierung Keine Angabe
Weblink
https://card2brain.ch/box/20170101_tbppeconomics_and_trends_in_the_plasma_industry
Einbinden
<iframe src="https://card2brain.ch/box/20170101_tbppeconomics_and_trends_in_the_plasma_industry/embed" width="780" height="150" scrolling="no" frameborder="0"></iframe>
material flow from the donor to the fractionator

donor selection --> blood/plasma collection --> testing of donations --> plasma release --> shipping to fractionator

material flow from the fractionator to the distributor

raw material release --> manufacturing --> QC testing --> product release --> shipping to markets

CLS plasma donation centers

most centers in USA and germany, more than 6'000 employees, more than 150 collection centers (logistics, storages, test labs etc.)

recovered vs source plasma

only 20% from recovered plasma (world), europe: 59%, africa: 70%, USA: 8%, great variation depending on region. Recovered plasma: 450 ml blood per donation, 220-250 ml plasma p.d., longer frequencies for donations, no donor compensation. Source Plasma (Apheresis): 600-800 ml, max. 2 donations/week, shorter frequencies for donations, donor compensation (20-30 Dollar per donation).

global plasma volume by region 2015

1'000 liters, recovered and apheresis. Only an increase in north america, United states = only country in sense of whole blood/plasma supply is entirely self-sufficient. America: 55.19% of plasma collection volume, china: 13.66%, germany: 6.75%

global plasma for fractionation by type

North America: plasma collection by apheresis increases continously since 2005, collection by recovered plasma slightly decreases. Europe: source plasma volume has more than doubled since 2005, whereas recovered plasma volume remains stable at still higher level.

plasma - the costs

cost components: materials, labour, indemnities (distribution, donor restoration..), overhead expenses. Share of costs: plasma processing industry: more than 50% production, 5% marketing. Conventional pharma industry: 5% production, 30% marketing. Point of reference for costs per litre: USD 150-200 (2 Bio. dollars total)

plasma products - potential for market expansion

specialty products: wound healing, fibrinogen, factor IX, prothrombin, API, inhibitors (low revenue, new gain methods and therapies needed, new markets and indications). 3 products cover 95% of the plasma gain: coagulation factor (VIII), albumin and immune globulin. use of recombinant products as alternatives to coagulation factors: for hemophilia A/B, recombinants are prophylactical and less immunogenic, for various therapeutic areas